Deuruxolitinib
also Leqselvi, CTP-543
- Approved (CTP-543, Leqselvi) · oral · JAK1/JAK2 inhibitor · Sun Pharma · FDA approved · Severe alopecia areata only
JAK inhibitor pill approved for severe alopecia areata
Deuruxolitinib, sold under the brand name Leqselvi, is a medication used for the treatment of alopecia areata. It is a Janus kinase inhibitor selective for JAK1 and JAK2. Although the relative effectiveness of deuruxolitinib and another Janus kinase inhibitor—baricitinib—for alopecia areata may vary depending on the population studied, both drugs are more effective than alternative treatments.
Read “Deuruxolitinib” on Wikipedia and its adverse effects · text from Wikipedia, CC BY-SA 4.0
Information, not medical advice. Talk to a licensed doctor or pharmacist before starting or changing a treatment.
Research 10
- Deuruxolitinib for Alopecia Areata.
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
- Success of Deuruxolitinib (Leqselvi™) in Extensively Treatment-Resistant Alopecia Universalis: A Case Report
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- Dose optimization of deuruxolitinib in adults with alopecia areata: A phase 2 randomized trial
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- The dose matters: Oral tofacitinib dose escalation or switching to deuruxolitinib for recalcitrant alopecia universalis and totalis, a retrospective case series
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Dose optimization of deuruxolitinib in adults with alopecia areata: A phase 2 randomized trial
- Pediatric alopecia areata and JAK inhibitors: Bridging the gap between evidence and practice
- JAK Inhibitors for Alopecia Areata: Approved Therapies, Efficacy, and Unanswered Questions
- Alopecia Areata: Current and Emerging Therapies
- Alopecia areata: Emerging therapies and up-to-date management strategies
- A Discrete Choice Experiment of Clinician Preferences Among Attributes of Approved Janus Kinase Inhibitors for Alopecia Areata
- Success of Deuruxolitinib (Leqselvi™) in Extensively Treatment-Resistant Alopecia Universalis: A Case Report
- Dupilumab and ritlecitinib combination therapy in a patient with alopecia totalis and atopic disease
- Therapeutic update on alopecia areata: a critical review of standard and emerging targeted therapies
- Patient preferences for treatment characteristics of Janus kinase inhibitors for alopecia areata: a discrete choice experiment